VCNX vs. MBIO, EYEN, AWH, PMCB, PHXM, AYTU, BCDA, KPRX, PHIO, and TLPH
Should you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Mustang Bio (MBIO), Eyenovia (EYEN), Aspira Women's Health (AWH), PharmaCyte Biotech (PMCB), PHAXIAM Therapeutics (PHXM), Aytu BioPharma (AYTU), BioCardia (BCDA), Kiora Pharmaceuticals (KPRX), Phio Pharmaceuticals (PHIO), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.
Vaccinex vs.
Vaccinex (NASDAQ:VCNX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
Vaccinex has higher revenue and earnings than Mustang Bio. Mustang Bio is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
Mustang Bio has a consensus price target of $100.00, suggesting a potential upside of 2,209.47%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts plainly believe Mustang Bio is more favorable than Vaccinex.
50.1% of Vaccinex shares are held by institutional investors. Comparatively, 9.9% of Mustang Bio shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 0.6% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.
In the previous week, Mustang Bio had 6 more articles in the media than Vaccinex. MarketBeat recorded 6 mentions for Mustang Bio and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 beat Mustang Bio's score of -0.07 indicating that Vaccinex is being referred to more favorably in the media.
Mustang Bio received 46 more outperform votes than Vaccinex when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 60.00% of users gave Vaccinex an outperform vote.
Summary
Mustang Bio beats Vaccinex on 8 of the 15 factors compared between the two stocks.
Get Vaccinex News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccinex Competitors List
Related Companies and Tools
This page (NASDAQ:VCNX) was last updated on 1/21/2025 by MarketBeat.com Staff
